Assembly Biosciences, Inc. officer and director Jason A. Okazaki filed a Form 144 notice on November 2, 2026, proposing to sell 6,202 shares of common stock on Nasdaq following a restricted stock unit release.
Key Highlights
- Seller: Jason A. Okazaki, identified in the filing as both an officer and director of Assembly Biosciences, Inc.
- Shares proposed for sale: 6,202 shares of common stock, with an aggregate market value of $121,657.81.
- Source of shares: The shares were acquired on October 30, 2026, through a restricted stock unit release from Assembly Biosciences, Inc.
- Approximate sale date: November 2, 2026, on the Nasdaq exchange, through broker Morgan Stanley Smith Barney LLC.
- Shares outstanding: According to the filing, 20,476,006 shares of common stock were outstanding at the time of the notice.
- Prior sales: The filing reports nothing to report for securities sold in the past three months by the person for whose account the securities are to be sold.
Okazaki's Proposed Rule 144 Sale of RSU-Released Shares
Assembly Biosciences, Inc. (NASDAQ:ASMB), headquartered at Two Tower Place, 7th Floor, South San Francisco, California, is the issuer named in this Form 144 notice. The filing was submitted by Jason A. Okazaki, who is listed as holding both officer and director roles at the company. The notice covers a proposed sale of 6,202 shares of common stock under Rule 144 of the Securities Act of 1933.
According to the filing, the shares were acquired on October 30, 2026, via a restricted stock unit release, with Assembly Biosciences, Inc. named as the person from whom the securities were acquired. The date of payment is listed as November 2, 2026, with the nature of payment listed as "N/A." The proposed sale is to be executed through Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 38th Floor, New York, NY 10004, with an approximate sale date of November 2, 2026.
The filing states that the aggregate market value of the shares to be sold is $121,657.81, against a total of 20,476,006 shares outstanding. Okazaki represented by signing the notice that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as stated in the form's attestation language. No sales activity was reported for the three months preceding this notice.
What Was Disclosed
Assembly Biosciences officer and director Jason A. Okazaki filed a Form 144 notice dated November 2, 2026, proposing to sell 6,202 restricted stock unit-released shares of common stock on Nasdaq, with an aggregate market value of $121,657.81, through Morgan Stanley Smith Barney LLC.




Please wait processing your request...